Abstract
Introduction
Colorectal cancer (CRC) is a significant public health problem. Annually, more than 1.36 million patients are diagnosed with CRC worldwide; approximately 694,000 CRC-associated mortalities occur each year, accounting for 8.5% of all cancer-related deaths and making CRC the third most common cause of death. 1 Although radical surgical resection and oxaliplatin-based adjuvant chemotherapy are standard therapeutic strategies, some patients receiving adjuvant chemotherapy ultimately develop recurrence or metastasis, representing a key barrier to the efficacy of CRC treatment. [2] [3] [4] [5] No reliable biomarker or indicator is currently known for predicting tumor recurrence or chemoresistance in CRC patients after oxaliplatin-based chemotherapy, and seeking new predictive biomarkers is thus warranted to prevent drug resistance and thereby improve patient prognoses. [6] [7] [8] In recent decades, postoperative adjuvant chemotherapy for colon cancer constitutes a major clinical advance in oncology. 5, 9 Adjuvant FOLFOX chemotherapy, which consists of leucovorin (LV), 5-fluorouracil (5-FU), and oxaliplatin, is one of the most widely used regimens after surgical resection. 10 In a multicenter international study on the use of FOLFOX4 as adjuvant treatment for colon cancer (NCT00275210), FOLFOX4 was demonstrated to prolong overall survival (OS) in patients with stage III colon cancer compared with patients who received 5-FU and LV without oxaliplatin. 4, 5 The addition of oxaliplatin to a regimen of 5-FU and LV is known as FOLFOX, which has become the gold standard adjuvant therapy for patients with stage III colon cancer. 5 Proper control of metabolic homeostasis is crucial for maintaining human physiology and health. The effects of diabetes mellitus (DM) on CRC have been debated; for instance, meta-analyses have consistently indicated that type 2 DM is an independent risk factor for developing CRC, 11, 12 and an increase in glycolytic activity by malignant tumor cells in vivo and in vitro has also been demonstrated. 13 Among Taiwanese patients with CRC, DM patients had a higher incidence of second malignancy than non-DM patients, 14 and DM patients have an increased risk of CRC and poorer outcomes compared with non-DM patients. [15] [16] [17] The potential impact on the clinical outcome of CRC patients with DM has received much attention. Under hyperglycemia, high glucose modulated the cytotoxicity of 5-FU in human colon cancer cells, 18 and diminished the chemotherapeutic effect of oxaliplatin plus 5-FU, leading to shorter survival in an animal model. 19 Although FOLFOX has become a standard chemotherapeutic regimen, no relevant information is currently available regarding the predictive value of blood sugar levels for CRC recurrence or chemoresistance after oxaliplatin-based chemotherapy, and the efficacy of oxaliplatin chemotherapy under hyperglycemia remains unclear. The aim of this study was to evaluate whether high blood sugar levels could affect the efficacy of adjuvant FOLFOX6 chemotherapy in patients with stage III CRC, as well as to explore the underlying signaling pathway of chemoresistence.
Materials and methods

Patients and tumor samples
In this retrospective study, patients with stage III CRC who had received oxaliplatin treatment and provided signed informed consent were included, but patients without records of fasting blood sugar (FBS) levels or incomplete medical records were excluded. Demographic information was obtained from 157 patients with primary stage III CRC 20 who received adjuvant FOLFOX6 chemotherapy at single institution in Taiwan between November 2009 and September 2015. Each FOLFOX cycle consisted of an oxaliplatin (85 mg/m 2 ) and folinic acid (400 mg/m 2 ) infusion on day 1, followed by a 46-h infusion of 5-FU (2800 mg/m 2 ) repeated every 2 weeks. 10 A total of 157 patients completed the adjuvant FOLFOX6 therapy (biweekly × 12 cycles for 6 months).
Impaired carbohydrate metabolism was defined as one of the ADA 2003 diagnostic criteria for diabetes (normal: <110 mg/dl; impaired fasting glucose: 110-125 mg/dl; fasting plasma glucose: ⩾126 mg/dl). 21, 22 Data of FBS levels were collected from all 157 CRC patients before CRC surgery. A total of 112 patients had fasting glucose levels between 75 and 125 mg/dl (<126 mg/dl, i.e. low blood glucose) and 45 had levels between 126 and 360 mg/dl (⩾126 mg/dl, i.e. high blood glucose). Diagnoses of DM were based on the patient's chart history of DM or previous use of antihyperglycemic agents for DM. All patients were unrelated ethnic Chinese residents of Taiwan. Each patient provided written informed consent for the collection and use of data/samples for research and publication of their case details. Furthermore, all patient data were anonymized. 
RNA extraction and mRNA quantitative assay
According to the manufacturer's instructions, approximately 10 7 cells were lysed in 1 ml of TRIzol reagent (Invitrogen). DNase treatment (Qiagen, Hamburg, Germany) was performed, and total RNA was purified with Qiagen RNeasy Columns (Qiagen). With random hexamer primers, cDNAs were synthesized from 1 μg of total RNA using reverse transcriptase (Applied Biosystems Inc., Foster City, CA, USA) and realtime polymerase chain reaction (RT-PCR) with SYBR Green (Applied Biosystems Inc.). Table 1 showed the demographic data of 157 stage II CRC patients (112 in the low blood glucose group versus 45 in the high blood glucose group), with a median blood sugar level of 105 mg/d, and median age of 63 years (20-93 years) . In this retrospective study, 28 patients with CRC had a history of DM and received different DM medications (Glucophage, Diamicron MR, Januvia, etc.) to control their blood sugar levels. Eight of the 28 CRC patients that received medication were able to maintain their blood sugar levels at <126 mg/dl ( Table 1 ). The patients with DM exhibited significantly higher blood sugar levels than patients without DM (p < 0.0001; Table 1 ). Table 1 also reveals significant differences in age (p = 0.019) and oxaliplatin resistance (p = 0.004) between the low-blood-glucose (<126 mg/dl) and high-blood-glucose (⩾126 mg/dl) groups; however, the two groups did not differ significantly in terms of other clinicopathological features such as sex, tumor size, tumor location, tumor invasion depth, lymph node metastasis, vascular invasion, perineural invasion, differentiation grade, or histological type (all p > 0.05). Figure 2D ). 
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Glycolysis-related mRNA or signaling pathway prediction assay
Our experiments demonstrated that high glucose concentrations enhanced cell proliferation in four colon cancer cell lines. We identified glycolysisrelated mRNAs or target genes that elucidated the proliferation and antioncogenic effects through Kyoto Encyclopedia of Genes and Genomes pathway program analysis and a literature review. The multifunctional transcription factors SMAD3 and MYC, as well as upregulation of EHMT2 expression, influenced cell survival and oxaliplatin resistance.
At high glucose concentrations, SMAD3 protein expression levels of SW620 cells were similarly unchanged, whereas phosphorylation of SMAD3 (pSMAD3) increased at high glucose concentrations. Increased pSMAD3 expression induced slightly increased MYC protein expression ( Figure 3 ). As shown in Figure 3 , protein expression levels of pSMAD3, pMYC, and EHMT2 increased significantly at high glucose concentrations (15 mM glucose; lane 2). However, after adding metformin (1 and 5 mM), the increase in phosphorylation of SMAD3 and MYC was reversed, and EHMT2 expression levels decreased (15 mM glucose; lanes 3 and 4, respectively).
Survival analysis
The DFS and OS of the 157 patients with stage III CRC were assessed using the Kaplan-Meier method ( Figure 4A and B, respectively). With 2 years as the endpoint, the DFS of the patients in the high-blood-glucose group (⩾126 mg/dl) was significantly poorer than that of patients in the low-blood-glucose group (<126 mg/dl; p = 0.012). However, with 3, 4, or over 4 years as the endpoint, the DFS of patients in the two groups was not significantly different (p = 0.050, p = 0.102, and p = 0.089, respectively). With 2 years as the endpoint, the OS of patients in the high blood glucose group (⩾126 mg/dl) was significantly poorer that of patients in the low blood glucose group (<126 mg/dl; p = 0.041). However, with 3, 4, or over 4 years as the endpoint, the OS of patients in the two groups was not significantly different (p = 0.063, p = 0.061, and p = 0.072, respectively).
Discussion
CRC is a human malignancy with a complex etiology, and the mechanisms underlying this pathophysiology are not yet completely understood. Epigenetic modifications have accounted for the majority of complex disease research; among these, blood sugar level reportedly serves as a potential cancer biomarker. 6, 27, 28 The most fundamental metabolic alteration in CRC cells is increased glycolysis. 13, 29 Glucose may drive cancer not only by modifying microRNA (miRNA) expression but also by activating the mammalian target of rapamycin, which can increase protein synthesis and cellular growth. [30] [31] [32] [33] [34] Through a series of in vitro studies, we demonstrated that high glucose concentrations enhanced cell proliferation and increased oxaliplatin resistance in four CRC cell lines. Another notable finding was that oxaliplatin resistance in these four CRC cell lines could be reversed by administering an anti-DM agent. Through the literature review, we observed that DM patients are at higher risk of carcinogenesis and death from cancer, including CRC, than healthy individuals. 19 Studies have shown that miRNA-16 partially induces cell cycle arrest by regulating multiple cell cycle genes, including cyclin D1, cyclin D3, cyclin E1, and CDK6, and prevents cells from entering the S phase, thus causing an accumulation of cells in G0/G1. 17, 35 The current study found that high glucose levels increased the proliferation of colon cancer cell lines HT-29, HCT-116, SW480, and SW620. Other in vivo studies have shown that chemotherapy with oxaliplatin and fluorouracil was less effective, and resulted in shorter survival under hyperglycemia. 19, 36 Studies have also found that MYC is overexpressed through glucose administration in many organs. 37, 38 By in vivo experiment in rats, Bux and colleagues, recently found that fed blood glucose levels increased from 125 ± 6 mg/dl to 512 ± 37 mg/dl, which was accompanied by a significant increase in gene transcript levels of the transcription factor MYC in the heart. 39 Transforming growth factor beta (TGFβ) signaling inhibited ezrin phosphorylation in a SMAD3-dependent manner, and regulated pro-apoptotic function through ezrinmediated protein kinase A activation. 40 The oxaliplatin resistance of CRC cells was mediated by inhibiting macroautophagy via the TGFβ/ SAMD4 pathway. 41 EHMT2 was reported to govern phenotype and chemoradioresistance in colon cancer stem cells. 42 EHMT2 and the colon cancer stem cell marker CD133A were significantly correlated in patients with advanced rectal cancer who received concurrent chemoradiotherapy; EHMT2 knockdown increased the sensitivity of cancer cells to radiation treatment. 42 This study demonstrated the biological plausibility of the hypothesis that hyperglycemia might increase SMAD3 and MYC phosphorylation in CRC patients ( Figure 3B ). MYC is a SMAD3 downstream protein whose phosphorylation is increased by phosphorylated SMAD3. Downstream EHMT2 can be upregulated by phosphorylated MYC. An increase in phosphorylation of the glucose-related target proteins SMAD3 and MYC under high glucose concentrations caused the upregulation of EHMT2 expression and oxaliplatin resistance in colon cancer cells.
One meta-analysis showed a significant association of type 2 DM with increased CRC risk. 15 The present data might indicate that patients with stage III CRC and high blood sugar levels exhibited markedly poor prognoses and oxaliplatin resistance during a short period. CRC survivors can change their diet and lifestyle with higher physical activity to control their serum blood sugar level, and thus potentially improve their prognosis and quality of life. We further stratified stage III CRC patients according to their serum blood sugar level and found that high blood sugar was correlated with a higher incidence of disease relapse, but that DM history was not. Because CRC patients with hyperglycaemia have poor clinical outcomes and higher oxaliplatin Cumulative survival rates for the 157 UICC stage III CRC patients assessed using the Kaplan-Meier method, and differences in survival rates analyzed using a log-rank test. (A) Disease-free survival. With 2 years as the endpoint, the DFS of patients in the high blood glucose group (⩾126 mg/dl) was significantly poorer than that of patients in the low blood glucose group (<126 mg/dl; p = 0.012). (B) Overall survival. With 2 years as the endpoint, the OS of patients in the high blood glucose group (⩾126 mg/dl) was significantly poorer that of patients in the low blood glucose group (<126 mg/dl; p = 0.041). Some limitations of this study should be mentioned. First, we examined only FBS levels, which reflect daily blood glucose levels but might be prone to bias. An HbA1c test can be performed at any time, regardless of the fasting duration or the content of the previous meal, and HbA1c levels reflect blood glucose levels over the preceding 6-8 weeks. 43 HbA1c levels may be more crucial for prognosis, but some of the patients in this study had incomplete data from HbA1c testing. Second, the peripheral neuropathy of the patients may be added as a study endpoint to differentiate DM-related peripheral sensory neuropathy. Third, the current study had a relatively small patient population and retrospective cohort. Therefore, multicenter prospective studies with data from FBS/HbA1c testing and peripheral neuropathy that might provide additional detailed information regarding the prognostic and adverse effects of adjuvant therapy on patients with stage III colon cancer are necessary.
In summary, the data in this study indicated that blood sugar levels can enhance oxaliplatin chemoresistance in vivo and CRC cell proliferation and chemoresistance in vitro. We suggest that blood sugar levels in patients with stage III CRC be used as a potential indicator for identifying increased risk of oxaliplatin chemoresistance within 2 years of radical resection.
